Member Info for Krone

“…. I look forward to discussing these latest advances with potential licensing partners."
Looking forward to the end of the jaw jaw and the beginning of the bidding war!

It’s an ill wind…..
https://endpts.com/astrazeneca-cuts-phiii-trial-short-after-next-gen-checkpoint-drug-fails-interim-analysis/

Hi HBD thanks, I guess we’ll find out in due course.

It appears that the CTA application process can take up to 60 days.
Assessment of your submission
The initial combined review assessment will be completed within 30 days of being submitted. Applications for healthy volunteer trials and sponsor-determined phase I trials in non-oncology patients may qualify for a shortened assessment time and MHRA will work with the research ethics committee to endeavour to expedite these applications. You should state on your covering letter if you think your trial is eligible. Note that trial designs that stretch to investigating the benefit of the treatment to participants may not be eligible for the expedited assessment timeframe……. ….Communication informing the applicant of the MHRA and ethics committee decision following receipt of the responses will usually be sent within 60 days of us receiving the original valid application. If an extension to the response date has been agreed this will impact the final decision timeline.
https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk

Positive on all fronts and bodes extremely well for near term success. Noticing that Medistrava no longer appearing as financial PR advisors?

As previously noted by Tim;
“ SRA737 is competitively positioned as potentially one of the leading clinical assets targeting the DNA damage repair (DDR) pathway with clinical safety & efficacy of SRA737 +/-LDG supporting standalone development and in combination with both PARP inhibitors (PARPi) and immuno-oncology (IO) therapy such as immune checkpoint blockade”
http://www.sareum.com/news/press-releases-and-news/2019/plc-key-takeaways-sra737-webcast-asco/

Regius Professor Johan De Bono has concentrated on prostate cancer and has extensive experience with SRA737
https://investor.sierraoncology.com/news-releases/news-details/2019/Sierra-to-Present-SRA737-Preliminary-Clinical-Data-and-Potential-Next-Steps-at-ASCO/default.aspx
https://www.cancerresearchuk.org/our-research/researchers/professor-johann-de-bono

Hi SOG - the Sierra/GSK deal was reportedly initiated, negotiated and agreed in around 2 months.

Excellent find Hotblack!

https://www.codexis.com/investors/news-events/press-releases/detail/331/codexis-announces-ceo-transition-effective-august-9-2022

https://twitter.com/arecor_plc/status/1549326775532113921?s=21&t=ljZqDTmkiAXxIt5j2JbZ7w
https://arecor.com/about-arecor/

Good morning C79 and many thanks for the links.
ATVB

Potential for SDC-1801 in the treatment of Sepsis previously flagged by Thoth2, C79 and others.
Conclusions IL6R blockade is causally associated with reduced incidence of sepsis, sepsis related critical care admission, and sepsis related mortality. These effects are comparable in size to the effect seen in severe COVID-19, where IL-6 receptor antagonists were shown to improve survival. This data suggests a randomised trial of IL-6 receptor antagonists in sepsis should be considered.
https://www.medrxiv.org/content/10.1101/2022.07.14.22277638v1

https://twitter.com/johncendpts/status/1547952260491067393?s=21&t=3Ze_2ckdskym10ygW74Zxw

Interesting Endpoints article in which Sierra gets a mention.
https://endpts.com/as-the-consumer-group-sails-away-on-monday-what-will-new-gsk-buy-now/

Outstanding research C79, please keep it coming and have a great weekend.

https://www.sciencedirect.com/science/article/abs/pii/S0960894X22003675

Hi Potnak, based on Tim’s track record I’m not convinced that “…they will use anything tangible to create a buzz”. Sareum just don’t do ‘buzz’! That said I would guess that Stephen Parker is keen to get the SP shifting a bit.

Thanks Potnak, yes, fully understand the situation but frankly find it wholly implausible that a significant stakeholder namely Sareum has no contractual leverage whatsoever. There will have been an agreement between Sareum and CRT in respect of the initial development of SRA737.
Perhaps the main takeaway from the Sierra debacle is for shareholders to be absolutely and categorically assured that any future agreements protect the interests of Sareum shareholders. I think I’ve banged on about this before….just killing time!

“Sixth Element Capital is currently managing the £70m CRT Pioneer Fund (CPF) to create the future of cancer therapy and diagnosis. CPF invests in oncology focused assets and companies. CPF’s investors are the European Investment Fund and Syncona.”
As the deal broker for the original Pronai/CRT agreement it is perhaps surprising that there has been no update since 12 January 2017.
https://www.sixthelementcapital.com/wp-content/uploads/2021/08/Transfer-of-Sponsorship-of-SRA737.pdf